sector medic suppli devic
 preview later alcon
messag ahead result updat model recent fx
fluctuat latest view contact len market see street expect
appropri estim larg line consensu
mix bag fx tax interest rate set meaning impact
earn meanwhil although major surpris alcon analyst
meet relat len busi came away increment concern
competit environ go get tougher next month
schedul report fiscal result market close thursday
decemb compar calcul back compani announc
result end august estim currenc increment headwind
quarter vs yet even take account estim
still roughli line current street consensu model call adjust
ep yoy total revenu organ model
coopervis sale underli basi coopersurg
grow organ
street expect look reason us aggreg well
lot move piec model adjust ep slightli
current consensu forecast revenu estim organ
street howev driven lower project part
delta may due currenc calcul would top line headwind
rate stay current level drag earn
reason ep estim also lower larg come tax
call manag guid effect tax rate street model
current set howev guidanc assum excess tax benefit relat stock-
base compens put context realiz tax benefit
ep stock comp estim compani like recogn
benefit technic possibl tailwind goe
zero next year view unlik scenario model assum
tax benefit stock-bas compens boost ep estim
interest rate anoth key variabl keep eye exit
float rate debt assum compani begin pay
aggress go forward stand right everi increas libor result
increment hit ep annual basi model assum averag
rate today
top line believ remain well posit continu take
share contact len market clearli acceler recent quarter
estim world-wide market growth ramp cc first nine month
margin out-performance vs peer
contract past month compani continu benefit over-
index exposur daili silicon hydrogel specialti len categori drive
major broader market growth model call organ growth roughli
stabl compar vs overal market growth rate
moder slightli cc vs cc still remain upper end histor
rang surgic side forecast acceler underli csi growth
driven eas fertil comp paragard roll
page analyst certif import disclosur
long-term one biggest question contact len competit landscap
whether alcon get back market growth compani held capit market
day yesterday new york ahead plan spin-off nv cover
guggenheim global pharmaceut analyst seamu fernandez manag
laid expect growth driver surgic vision care busi len
side estim alcon track lose share fourth consecut year
impress success daili daili sih segment
off-set weak rest portfolio under-perform meant
continu benefit struggl least one major competitor
even bhc driven improv momentum len busi
late hear anyth yesterday would lead us believ scenario chang
spin potenti ad element distract near-term
howev expect independ alcon improv competitor
long-term product perspect compani bank launch new
daili sih len reinvigor contact franchis limit launch plan
global roll-out expect earli alcon intend posit
best-in-class offer within mainstream daili sih segment pit head-to-head
clariti along bausch aqualox len recent launch
japan figur increas competit pressur within categori estim could
account sale high end daili sih market alcon
also target launch daili toric within next month continu
invest multifoc offer beyond compani intend launch two new
innov contact len platform one appear follow-on
water gradient categori also continu develop accommod contact len
page analyst certif import disclosur
straddl line healthcar consum product contact
len women health busi coopervis portfolio uniqu posit take
advantag two tailwind drive contact len market growth today shift
premium len materi particular silicon hydrogel increas popular
daili dispos lens recent year leverag broadest daili sih
offer market lead posit monthli sih categori continu
long histori above-market growth compani captur averag
market share per year sinc expect gain moder go forward
backdrop competit contact len market believ cooper
remain well posit sustain growth
elsewher paragard deal ad scale coopersurg grow women health
presenc often overlook investor expect csi account
overal revenu growth fuel
primarili compani invest dozen deal
past decad build lead posit ivf genet test market follow
acquisit paragard intrauterin devic believ
long-term fundament market appeal see grow scale csi
neg broader invest case complic stori believ
investor would prefer look sole contact len play
share current trade ntm ep ntm ebitda
repres premium large-cap med-tech group averag price-to-earnings
ev/ebitda basi superior top line growth rate vs
large-cap group would seem argu premium valuat dont see
compani sustain bottom line growth trajectori meaning differenti
group averag also view cooper outsiz exposur currenc swing
rise interest rate consum categori believ could prove highli
cyclic next econom downturn argument multipl expans
result maintain neutral rate
upsid risk rate includ faster expect contact len market growth due
rise sih penetr daili len adopt increas share gain
busi better expect growth/accret paragard
downsid risk rate includ better anticip traction competit
contact len launch weaken macroeconom backdrop put pressur
cooper busi see discretionari med-tech market
potenti exposur strong dollar rise interest rate
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
compani report guggenheim secur llc estim
page analyst certif import disclosur
